Studies on the efficacy of pyrotinib in the treatment of HER-2 positive advanced solid tumors.

被引：0
|
作者：
Fan, Shaoshuang
Jiang, Da
Lv, Yalei
Cui, Yanzhi
Kong, Yan
Dong, Qian
Huang, Fang
Zhang, Xue
Wang, Long
Zhou, Xinliang
Jin, Hui
Li, Ying
Hou, Ran
机构：
[1] Hebei Med Univ, Hosp 4, Shijiazhuang, Hebei, Peoples R China
[2] Hebei Med Univ, Hosp 4, Dept Med Oncol, Shijiazhuang, Hebei, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e15639
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Correlation of serum HER-2/neu extracellular domain levels in metastatic breast cancer with the expression of HER-2/neu determined by immunohistochemistry in primary tumors.
    Witzel, I
    Thomssen, C
    Pantel, K
    Neumann, R
    Carney, W
    Loening, T
    Jaenicke, F
    Mueller, V
    BREAST CANCER RESEARCH AND TREATMENT, 2003, 82 : S143 - S143
  • [32] Pyrotinib in the Treatment of Women With HER2-Positive Advanced Breast Cancer: A Multicenter, Prospective, Real-World Study
    Zhang, Lili
    Wu, Xiaohong
    Zhou, Jun
    Zhu, Mingzhen
    Yu, Hao
    Zhang, Yusong
    Zhao, Yutian
    Han, Zhengxiang
    Guo, Yujiang
    Guan, Xiaoqing
    Wang, Xufen
    Xu, Hong
    Sun, Li
    Zhang, Jiaxin
    Zhuang, Min
    Xie, Li
    Yu, Shiyou
    Chen, Ping
    Feng, Jifeng
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [33] A novel therapy based on SBRT targeting HER-2 expression advanced solid tumors (PRaG 3.0 Regimen)
    Xu, Meiling
    Kong, Yuehong
    Xing, Pengfei
    Zhang, Junjun
    Zhao, Xiangrong
    Zhang, Liyuan
    RADIOTHERAPY AND ONCOLOGY, 2024, 197 : S262 - S263
  • [34] Binary oncolytic adenovirus in combination with HER2-specific autologous CAR VST for treatment of advanced HER2-positive solid tumors (VISTA).
    Makawita, Shalini
    Gibbs, Jerry M.
    McFadden, Dustin R.
    Porter, Caroline
    Shaw, Amanda Rosewell
    Robertson, Catherine
    Woods, Mae Louise
    Wang, Tao
    Grilley, Bambi J.
    Heslop, Helen E.
    Brenner, Malcolm K.
    Suzuki, Masataka
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [35] Efficacy and tolerability of neoadjuvant Pertuzumab, Trastuzumab, and weekly Paclitaxel in Locally advanced Her-2 positive Breast cancer
    Gupta, Niraj
    Giblin, Erica
    Spivey, Tara
    Govert, Kristen
    Leagre, Christopher
    Liebross, Robert
    Tumati, Vasu
    Dugan, Thomas
    Yadav, Rina
    Henman, Patrick
    Beaudrie, Nick
    Bair, Tessa
    Durk, Jessica
    Hancock, Marjaorie
    Engle, Trisha
    Myers, Michelle
    Schneiders, Julie
    Tigges, Thomas
    CANCER RESEARCH, 2021, 81 (04)
  • [36] Cardiotoxicity in HER-2 positive patients, with advanced breast cancer, receiving several years of treatment with trastuzumab
    Larsen, A. K.
    Jensen, A. B.
    Langkjer, S. T.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : S183 - S184
  • [37] Pyrotinib maleate for the treatment of brain metastases from HER2-positive solid tumours: A real-world study
    Wu, Qichao
    Wang, Kuanyu
    Sun, Shibin
    Ding, Xiaosheng
    Hua, Yichun
    Li, Xiaoyan
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [38] Pyrotinib as a therapeutic for HER2-positive breast cancer
    Kioutchoukova, Ivelina
    Lucke-Wold, Brandon P.
    TRANSLATIONAL CANCER RESEARCH, 2023, 12 (06) : 1376 - 1379
  • [39] Treatment of infra-centimetric HER2-positive(+) invasive breast tumors. The Institut Curie experience
    Cottu, P. H.
    Rodrigues, M. J.
    Kirova, Y.
    Vincent-Salomon, A.
    CANCER RESEARCH, 2009, 69 (02) : 248S - 248S
  • [40] Immunohistochemical characterization of HER-2 tumors
    Cuesta, A.
    Honrado Franco, E.
    Baltasar Moreira, M.
    Castro Val, P.
    Izquierdo Garcia, F.
    VIRCHOWS ARCHIV, 2013, 463 (02) : 102 - 102
12345